171 related articles for article (PubMed ID: 2021547)
21. The prognostic significance of transforming growth factors in human breast cancer.
Murray PA; Barrett-Lee P; Travers M; Luqmani Y; Powles T; Coombes RC
Br J Cancer; 1993 Jun; 67(6):1408-12. PubMed ID: 8390290
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.
Wärri AM; Huovinen RL; Laine AM; Martikainen PM; Härkönen PL
J Natl Cancer Inst; 1993 Sep; 85(17):1412-8. PubMed ID: 8350365
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.
Kopp A; Jonat W; Schmahl M; Knabbe C
Cancer Res; 1995 Oct; 55(20):4512-5. PubMed ID: 7553618
[TBL] [Abstract][Full Text] [Related]
24. Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers.
Delvenne CG; Winkler-Gol RA; Piccart MJ; Hustin J; Michaux D; Leclercq G; Nogaret JM; Autier P
Eur J Cancer; 1992; 28(2-3):700-5. PubMed ID: 1350458
[TBL] [Abstract][Full Text] [Related]
25. Determination of transforming growth factor beta 1 mRNA expression in breast carcinomas by in situ hybridization.
Walker RA; Gallacher B
J Pathol; 1995 Oct; 177(2):123-7. PubMed ID: 7490677
[TBL] [Abstract][Full Text] [Related]
26. Correlation of TGF-beta 1 expression with medroxyprogesterone acetate responsiveness in mouse mammary adenocarcinomas.
Elizalde PV; Guerra FK; Gravano M; Lanari C; Lippman ME; Charreau EH; Lupu R
Cancer Invest; 1995; 13(2):173-80. PubMed ID: 7874571
[TBL] [Abstract][Full Text] [Related]
27. Induction of transforming growth factor beta in hormonally treated human prostate cancer.
Muir GH; Butta A; Shearer RJ; Fisher C; Dearnaley DP; Flanders KC; Sporn MB; Colletta AA
Br J Cancer; 1994 Jan; 69(1):130-4. PubMed ID: 8286194
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
Murphy CS; Pink JJ; Jordan VC
Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
[TBL] [Abstract][Full Text] [Related]
29. Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells.
Nutt JE; Harris AL; Lunec J
Br J Cancer; 1991 Oct; 64(4):671-6. PubMed ID: 1911215
[TBL] [Abstract][Full Text] [Related]
30. Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients.
Mirza MR
Cancer Treat Rev; 1991 Jun; 18(2):145-8. PubMed ID: 1804525
[TBL] [Abstract][Full Text] [Related]
31. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
32. Transcripts for transforming growth factors in human breast cancer: clinical correlates.
Barrett-Lee P; Travers M; Luqmani Y; Coombes RC
Br J Cancer; 1990 Apr; 61(4):612-7. PubMed ID: 2331446
[TBL] [Abstract][Full Text] [Related]
33. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
34. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
35. Role of TGF beta in the anti-estrogen response/resistance of human breast cancer.
Benson JR; Baum M; Colletta AA
J Mammary Gland Biol Neoplasia; 1996 Oct; 1(4):381-9. PubMed ID: 10887512
[TBL] [Abstract][Full Text] [Related]
36. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer.
Yoo YA; Kim YH; Kim JS; Seo JH
Biochim Biophys Acta; 2008 Mar; 1783(3):438-47. PubMed ID: 18164268
[TBL] [Abstract][Full Text] [Related]
37. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
[TBL] [Abstract][Full Text] [Related]
38. Towards a molecular basis for tamoxifen resistance in breast cancer.
Johnston SR; Dowsett M; Smith IE
Ann Oncol; 1992 Jul; 3(7):503-11. PubMed ID: 1498070
[TBL] [Abstract][Full Text] [Related]
39. [Tamoxifen in the treatment of breast cancer].
Charlier C; Colin C; Merville MP; Gielen J; Lambotte R; Plomteux G; Castronovo V
J Gynecol Obstet Biol Reprod (Paris); 1994; 23(7):751-6. PubMed ID: 7822705
[TBL] [Abstract][Full Text] [Related]
40. [Recent progress of endocrine therapy in breast cancer].
Nomura Y
Gan To Kagaku Ryoho; 1992 Jun; 19(6):783-9. PubMed ID: 1605654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
